Gold prices hold losses as US-EU trade deal eases safe‑haven demand
BOTHELL, Wash.—Mathew Aby J., Executive Vice President and Chief Scientific Officer at Biolife Solutions Inc. (NASDAQ:BLFS), recently sold a portion of his holdings in the company. According to a Form 4 filing with the Securities and Exchange Commission, Aby sold 425 shares of common stock on March 3, 2025. The shares were sold at a price of $25.46 each, amounting to a total transaction value of $10,820. The transaction comes as BLFS shares have shown significant momentum, posting a 46% gain over the past year, though InvestingPro analysis indicates the stock is currently trading above its Fair Value.
Following this transaction, Aby holds 262,198 shares of Biolife Solutions. The sale was conducted under a pre-established Rule 10b5-1 trading plan, which was adopted to satisfy tax withholding obligations related to the vesting of restricted stock. InvestingPro data reveals the company maintains strong liquidity with a current ratio of 4.54 and operates with minimal debt, showing a debt-to-equity ratio of just 0.05.
Biolife Solutions, headquartered in Bothell, Washington, specializes in the development and production of biopreservation media products for cells, tissues, and organs. The company maintains a solid gross profit margin of 65% despite current market challenges. For deeper insights into BLFS’s insider trading patterns and 6 additional ProTips, visit InvestingPro.
In other recent news, BioLife Solutions announced its fourth-quarter financial results, reporting revenues of $22.7 million, which exceeded several analysts’ expectations. The company experienced a 31% year-over-year increase in revenue, driven by a 37% rise in its Cell Processing segment, which reached $20.3 million. BioLife Solutions reported a narrower-than-expected loss of $0.04 per share, beating analyst estimates of a $0.08 loss per share. Benchmark maintained its Buy rating on the company’s stock, with a target price of $30, following these positive results. The firm highlighted the company’s strong performance and optimistic financial outlook as key factors for its endorsement. BioLife Solutions provided an upbeat guidance for 2025, projecting revenue growth of 16% to 20%, with anticipated revenues between $95.5 million and $99 million. The company also expects Cell Processing revenue to grow between 18% and 21%, reaching $86.5 million to $89 million. BioLife Solutions noted that its biopreservation media is now integrated into 17 approved cell and gene therapies, with additional approvals expected in the coming year.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.